Psychosis in Parkinson's disease

被引:70
|
作者
Poewe, W [1 ]
机构
[1] Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria
关键词
Parkinson's disease; psychosis; atypical neuroleptics; hallucination; cholinesterase inhibitors;
D O I
10.1002/mds.10566
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Psychosis is a disabling nonmotor complication of Parkinson's disease (PD). Visual hallucinations are the most common clinical manifestation and have been observed in up to 40% of patients with advanced disease in hospital-based series. Age, cognitive dysfunction, depression, as well as severity and duration of disease have all been identified as risk factors in multiple studies. All major anti parkinsonian drugs can induce psychosis in at-risk patients. Early drug-induced psychosis has been observed in up to 16% of patients treated with dopamine agonists and has been associated with increased risk for the development of dementia later on. Management of psychosis in PD is complex and includes control of potential triggers and reductions of polypharmacy as well as the addition of atypical antipsychotics. Cholinesterase inhibitors may prove an additional option in psychotic PD patients with dementia. (C) 2003 Movement Disorder Society.
引用
收藏
页码:S80 / S87
页数:8
相关论文
共 50 条
  • [41] Treatment of Psychosis and Dementia in Parkinson’s Disease
    Jennifer G. Goldman
    Samantha Holden
    Current Treatment Options in Neurology, 2014, 16
  • [42] Diagnosis and management of psychosis in Parkinson's disease
    Latoo, Javed
    Mistry, Minal
    Dunne, Francis J.
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2012, 16 (05) : 7 - 10
  • [43] Cannabidiol for the treatment of psychosis in Parkinson's disease
    Zuardi, A. W.
    Crippa, J. A. S.
    Hallak, J. E. C.
    Pinto, J. P.
    Chagas, M. H. N.
    Rodrigues, G. G. R.
    Dursun, S. M.
    Tumas, V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S417 - S418
  • [44] Psychosis in Parkinson's disease: Case studies
    Salter, Brian C.
    Anderson, Karen E.
    Weiner, William J.
    NEUROLOGIC CLINICS, 2006, 24 (02) : 363 - +
  • [45] Scales to evaluate psychosis in Parkinson's disease
    Goetz, C. G.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S9 - S9
  • [46] Cannabidiol for the treatment of psychosis in Parkinson's disease
    Zuardi, A. W.
    Crippa, J. A. S.
    Hallak, J. E. C.
    Pinto, J. P.
    Chagas, M. H. N.
    Rodrigues, G. G. R.
    Dursun, S. M.
    Tumas, V.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2009, 23 (08) : 979 - 983
  • [47] Ziprasidone in the treatment of Parkinson's disease psychosis
    Shiah, I-Shin
    Lin, Chun-Lung
    Mao, Wei-Chung
    Luu, Sy-Ueng
    EUROPEAN PSYCHIATRY, 2006, 21 (08) : 578 - 579
  • [48] Aripiprazole in psychosis associated with Parkinson's disease
    López-Meza, E
    Ruiz-Chow, A
    Ramirez-Bermudez, J
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2005, 17 (03) : 421 - 422
  • [49] Parkinson's disease and psychosis: Report of a case
    Valverde Barea, M.
    Espana Osuna, A.
    Cartas Moreno, F.
    EUROPEAN PSYCHIATRY, 2017, 41 : S843 - S844
  • [50] Depression, psychosis and dementia in Parkinson's disease
    Baker, MG
    NEUROLOGY, 1999, 52 (07) : S1 - S1